More on SRNE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)
- Holders

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Sorrento Therapeutics (NQ:SRNE)
Delayed: 9.46 +0.59 (6.65%)
Prev. Close $8.87  
Open$9.45 
52 Wk High$10.26 
52 Wk Low$4.25 
Day High$10.27 
Day Low$9.36 
P/E N/A  
EPS$-0.50 
Volume19,820,784 

Friends, Peers and Foes (?): WFC, CLNY, L1PA, HEBT, BSGM (more...)

Jun 11, 2021 04:11 PM Sorrento Therapeutics (SRNE) Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Jun 11, 2021 04:11 PM Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Jun 11, 2021 09:06 AM Sorrento (SRNE) Announces Pact With Mayo Clinic and FDA Clearance for First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
Jun 11, 2021 09:00 AM Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients W
Jun 4, 2021 04:05 PM Form 8-K Sorrento Therapeutics, For: Jun 01
Jun 4, 2021 03:14 PM Sorrento Therapeutics (SRNE) Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166
Jun 4, 2021 03:13 PM Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Jun 4, 2021 01:03 PM Sorrento Therapeutics (SRNE) Enters collaborative Agreement with NextGenN
Jun 4, 2021 01:00 PM Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Brin
Jun 2, 2021 09:00 AM Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
View All Articles